Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Emphysema by Phase

  • There are currently 89 ongoing clinical trials involving Emphysema

  • Of the 89 trials,48 trials are in Phase III

  • Furthermore, 16 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Emphysema by Phase

Published: October 2021
Source: GlobalData

The global pharmaceutical industry is steadily developing new drugs for Emphysema, a Respiratory condition. The largest number of ongoing clinical trials for Emphysema is in the Asia-Pacific region. North America and Europe are among some of the other prominent regions involved in Emphysema-related drug trials.

Emphysema related clinical trials sponsors 

University of Pittsburgh, University of Alabama at Birmingham, Leiden University Medical Center, Grifols SA, and Celon Pharma SA are a few notable clinical trial sponsors involved in Emphysema. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Emphysema  

Budesonide and formoterol fumarate (Symbicort, Vannair, Symbicortmite, Sinestic, Rilast, Rilast Forte), Tiotropium bromide (Spiriva/ Spiriva Respimat/ Favint/ Favint Respimat/ Favynd/ Srivasso, Spiriva Handihaler), and Fluticasone propionate and Salmeterol xinafoate (Advair, Seretide, Seretide Diskus, Fluterol, Brisair, Vaini) are among the key marketed drugs involving Emphysema.

Budesonide and formoterol fumarate (Symbicort, Vannair, Symbicortmite, Sinestic, Rilast, Rilast Forte) is a fixed-dose combination drug, acts as an anti-inflammatory and bronchodilator agent. It functions via the Beta 2 Adrenergic Receptor (Beta 2 Adrenoreceptor or ADRB2) Agonist; Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1) Agonist mechanism of action. It is formulated as an aerosol, powder, suspension for an inhalational route of administration. It is indicated in the regular treatment of asthma where the use of a combination (inhaled corticosteroid and long-acting beta-2 adrenoceptor agonist) is appropriate. Budesonide and formoterol fumarate was first approved in 2000 and is marketed in the US, the UK, France, Germany, China, and Japan by AstraZeneca Plc.

Tiotropium bromide (Spiriva/ Spiriva Respimat/ Favint/ Favint Respimat/ Favynd/ Srivasso, Spiriva Handihaler) is an anticholinergic agent and bronchodilator.It functions via the Muscarinic Acetylcholine Receptor M3 (CHRM3) Antagonist mechanism of action. It is formulated as capsules, powder, solutions for inhalational use. It is indicated for the treatment of bronchospasm associated with chronic obstructive pulmonary disease, chronic bronchitis, and emphysema. Spiriva Respimat is also indicated for the long-term, once-daily, maintenance treatment of asthma in patients 6 years of age and older. Tiotropium bromide was first approved in 2001 and is marketed in the US, the UK, France, Germany, China, and Japan by Boehringer Ingelheim International GmbH.

Related Data & Insights

Number of ongoing Clinical Trials (for drugs) involving Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) by Phase

Number of ongoing Clinical Trials (for drugs) involving Pancreatic Cancer by Phase

Number of ongoing Clinical Trials (for drugs) involving X-Linked Hypophosphatemic Rickets by Phase

Number of ongoing Clinical Trials (for drugs) involving Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) by Phase

Number of ongoing Clinical Trials (for drugs) involving Restenosis by Phase

Number of ongoing Clinical Trials (for drugs) involving Brain Cancer by Phase

Related Companies

Johnson & Johnson

United States of America

HCA Healthcare Inc

United States of America

Pfizer Inc

United States of America

AbbVie Inc

United States of America

Bayer AG

Germany

Sanofi

France

Novartis AG

Switzerland

AstraZeneca Plc

United Kingdom

Still looking?

Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward